PHPeter W. Hamer

Peter W. Hamer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peter W. Hamer has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • B Elliott

    School of Human Movement and Exercise Science, University of Western Australia

    1 shared publication
  • Benjamin L. Woodham

    Department of Surgery, Christchurch Hospital, Christchurch, New Zealand

    1 shared publication
  • C Finch

    NSW Injury Risk Management Research Centre, University of New South Wales

    1 shared publication
  • Dean L. Harris

    Canterbury Regional Cancer and Haematology Service, Christchurch Hospital, Christchurch, New Zealand

    1 shared publication
  • Gavin Jon Pinniger

    School of Human Sciences, The University of Western Australia, Crawley, Western Australia, Australia

    1 shared publication
  • Ian G. Ward

    Canterbury Regional Cancer and Haematology Service, Christchurch Hospital, Christchurch, New Zealand

    1 shared publication

Latest Publications

  • Stricture rate after chemoradiotherapy and radiotherapy for oesophageal squamous cell carcinoma: a 20‐year experience

    by Peter W. Hamer, Stephanie C. Hight, Ian G. Ward, Dean L. Harris, Benjamin L. Woodham, Richard S. Flint

    Background Definitive chemoradiation for oesophageal squamous cell carcinoma (SCC) is the first‐line treatment in many centres. However, it is not without morbidity. We assess outcomes for patients treated with definitive chemoradiotherapy and radiotherapy. Methods A retrospective review of a prospectively maintained database (Radiotherapy Department, Canterbury District Health Board) was undertaken. All patients who underwent definitive radiotherapy for oesophageal SCC between October 1996 and April 2015 were included. Results Sixty patients underwent chemoradiotherapy with curative intent and 17 underwent definitive radiotherapy with curative intent. Median age was 69 years (44–84 years) for those undergoing chemoradiotherapy and 73 years (36–85 years) for those who underwent definitive radiotherapy. Tumour location in all patients was upper third in 14 (18%), middle third in 39 (51%), lower third in 22 (29%) cases and junctional tumour in two (3%). Staging information was complete for 73 of 77 patients (stage I 16/77 (21%), stage II 40/77 (52%), stage III 17/77 (22%)). Median dose of external beam radiotherapy for those who underwent definitive chemotherapy was 50.4 Gy (30–63 Gy) and 60 Gy (50–64 Gy) for definitive radiotherapy. Median length of follow‐up was 39 months (range 4–120 months). Strictures developed in 58% of all patients (52% chemoradiotherapy and 76% definitive radiotherapy). Twenty‐four (32%) patients were dilated and 14 (18%) stented. The chemoradiotherapy group had higher 5‐year survival than definitive radiotherapy group (34% versus 6%, P = 0.0034). Conclusion Oesophageal SCC treated with chemoradiation has a 5‐year survival rate of 34%. Post‐treatment strictures occur in 52% of patients with chemoradiotherapy and 76% with definitive radiotherapy.


  • The physiological effects of IGF-1 (class 1:Ea transgene) over-expression on exercise-induced damage and adaptation in dystrophic muscles of mdx mice

    by James A. Ridgley, Gavin J. Pinniger, Peter W. Hamer, Miranda D. Grounds

    Duchenne muscular dystrophy (DMD) is a genetic disorder in which muscle weakness and fragility contribute to ongoing muscle degeneration. Although exercise-induced muscle damage is associated with adaptation that protects normal muscle from further damage, exploiting this process to protect dystrophic muscle has been avoided for fear of inducing excessive muscle degeneration. However, muscle-specific over-expression of the class 1:Ea isoform of insulin-like growth factor-1 (IGF-1) reduces myofibre necrosis in dystrophic mdx mice (a model for DMD) and, therefore, may enhance the adaptation process in response to eccentric exercise. To test this hypothesis, we evaluated the effect of transgenic class 1:Ea IGF-1 over-expression on the susceptibility to muscle damage and subsequent adaptation in 12-week-old dystrophic mdx and non-dystrophic control mice. Experiments were conducted in vivo using a custom-built isokinetic mouse dynamometer to measure the deficit in joint torque (indicating muscle damage) after 20 maximal lengthening (eccentric) contractions. Adaptation to this damaging exercise was evaluated by repeating the protocol 7 days after the initial exercise. The over-expression of IGF-1 significantly increased the normalised joint torque in non-dystrophic mice and appeared to ameliorate the muscle weakness in dystrophic mice. All mice displayed a marked reduction in the susceptibility to muscle damage on day 7; however, this adaptation was unaffected by IGF-1, showing that IGF-1 does not protect the dystrophic muscles of adult mdx mice against damage resulting from maximal lengthening contractions.


  • Open Access

    The Western Australian sports injury study

    by M Stevenson, C Finch, P Hamer, B Elliott